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Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Se-
quencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid
deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of
cefepime.
CMY-2 is the most commonly encountered plasmid-medi-
ated class C -lactamase, often found in Escherichia coli and
Salmonella enterica serovars (10, 13). The spectrum of resis-
tance conferred by CMY-2 is typical of class C enzymes:
CMY-2 confers resistance to penicillins, cephalosporins (in-
cluding cephamycins), and aztreonam. In contrast, gram-neg-
ative bacteria harboring CMY-2 are susceptible to cefepime.
Cefepime, a cephalosporin with methoxyimino and aminothia-
zolyl moieties, is a substrate that is stable against hydrolysis by
most class C -lactamases, both chromosomal and plasmid
mediated. Here, we report the identification of two variants of
CMY-2 -lactamases, designated CMY-33 and CMY-44,
which confer reduced susceptibility to cefepime.
E. coli strains producing these variants were isolated from
three unrelated patients who were admitted to the University
of Pittsburgh Medical Center (UPMC) Presbyterian Campus
between 2006 and 2008. The E. coli strains under study were
bloodstream and urinary tract isolates. Two of the patients
received cefepime for 6 to 10 days within the 2 months pre-
ceding the isolation of the organisms. The MICs of the repre-
sentative -lactams for these clinical isolates were measured by
Etest (AB Biodisk, Solna, Sweden). According to the Etest
results, the E. coli isolates were all highly resistant to oxyimi-
nocephalosporins, including cefuroxime, ceftazidime, and ce-
fotaxime, and also showed reduced susceptibility to cefepime
(MIC range, 6 to 96 g/ml) (Table 1). Analytical isoelectric
focusing revealed -lactamase activity with pIs of 9.0 for all
isolates and 5.4 for isolates YD006 and 34943, suggesting the
presence of class C -lactamases and TEM-1, respectively
(data not shown). To define the -lactamases causing the ex-
tended-spectrum cephalosporin resistance, PCR and se-
quencing were performed to detect the blaTEM-, blaSHV-,
and blaCTX-M-type extended-spectrum -lactamase (ESBL)
genes (4). For the amplification and sequencing of the
blaCMY-2-type -lactamase genes, the following primer set
was used: CMY-flanking-F (5-CCGGACACCTTTTTGCT
TTT-3) and CMY-flanking-R (5-TATCCTGGGCCTCATC
GTCAGTTA-3). The PCR amplification identified blaTEM-1
in isolates YD006 and 34943 but no class A ESBL genes in any
of the isolates. In contrast, the PCR amplified blaCMY in all
three isolates. The conjugal transfer of the blaCMY gene using
E. coli J53 Azir (azide resistant) as the recipient (kind gift from
George A. Jacoby) was successful with E. coli 34943 but not
with E. coli 1285 or E. coli YD006. However, a plasmid was
successfully transformed into E. coli DH10B by electropora-
tion for all three isolates, indicating the plasmidic location of
these blaCMY-2 variants. These plasmids appeared unrelated to
each other by restriction endonuclease digestion (Fig. 1). The
plasmid from E. coli YD006 conferred resistance to tetracy-
cline, chloramphenicol, and sulfisoxazole in addition to ceph-
alosporins; resistance to aminoglycosides was not observed.
The plasmids from E. coli 1285 and 34943 only conferred
resistance to cephalosporins. Sequencing analysis revealed the
presence of novel CMY-2 variants, blaCMY-33 in isolates 1285
and YD006 and blaCMY-44 in isolate 34943, respectively. A
two-amino-acid deletion (Leu293 and Ala294) was detected in
the translated sequence of blaCMY-33 compared with that of the
other CMY-2 variant. The translated sequence of blaCMY-44
had an additional two-amino-acid deletion of Ala295 and
Leu296 compared with that of blaCMY-33 (Fig. 2). These dele-
tions were located within or in the proximity of the H-10 helix
of the enzymes (alternatively, referred to as the R2 loop) (7).
In class C -lactamases, certain amino acid deletions in the
H-10 helix are implicated in the broadening of the substrate
spectrum to include cefepime (2, 5, 8). To establish the role of
these deletions in the reduced susceptibility to cefepime, iso-
genic E. coli strains producing CMY-2, CMY-33, or CMY-44
were constructed. In brief, the three blaCMY genes were am-
plified by PCR and directionally cloned to vector pBCSK as
described previously (3). E. coli DH10B was then transformed
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with these recombinant plasmids. The MICs against represen-
tative -lactams are presented in Table 1.
The E. coli DH10B strains producing CMY-33 and CMY-44
demonstrated reduced susceptibility to cefepime compared
with that producing CMY-2 by 12- to 24-fold, whereas resis-
tance to ceftazidime and cefotaxime was maintained (Table 1).
On the other hand, the MICs of cefuroxime and cefoxitin,
which are usually excellent substrates of class C -lactamases
including CMY-2, were lowered for isolates producing
CMY-33 and -44. These results suggested that the amino acid
deletions observed in CMY-33 and -44 may be responsible for
the reduced cefepime susceptibility in these clinical isolates.
Given the variable degree of resistance to cefepime among the
clinical isolates, however, it is plausible that other mechanisms
augmenting cefepime resistance are present, especially in iso-
late 1285.
Certain amino acid changes (insertions, deletions, or substi-
tutions) in the H-10 helix are believed to result in structural
alterations that enable better accommodation of the R2 side
chains of cephalosporins, including cefepime, into the active
site of class C -lactamases and thus enhance the hydrolysis of
these substrates (7). Examples of insertions and substitutions
in class C enzymes that lead to a clinically significant reduction
of cefepime susceptibility include chromosomal AmpC of E.
coli BER (9) and Enterobacter aerogenes Ear2 (1) and plasmid-
mediated CMY-19 in Klebsiella pneumoniae (12). Examples of
deletions leading to this property include chromosomal AmpC
of Enterobacter cloacae CHE (2), Serratia marcescens HD (8),
and E. coli HKY28 (5). All of these variant enzymes were
reported as sporadic events, and the understanding is that
cefepime maintains excellent activity against organisms pro-
ducing class C -lactamases (11). However, our finding of
three independent clinical cases producing two CMY-2 vari-
ants with this property during a relatively brief period of
time suggests that blaCMY-2, the most common plasmid-
mediated class C -lactamase gene in E. coli, has the po-
tential to develop variants with reduced susceptibility to
cefepime, likely under the selective pressure from excessive
use. Clinical microbiologists should be aware that reduced
susceptibility to cefepime may occur in variants of CMY-2,
which are not easily identified in the clinical laboratory and
thus may be overlooked. The continuing discovery of plas-
FIG. 1. Plasmid restriction analysis of the blaCMY-bearing plasmids
in E. coli DH10B transformants corresponding to the clinical isolates.
Lane M, molecular weight markers ( DNA-HindIII digest [New En-
gland Biolabs, Ipswich, MA] plus GeneRuler 100-bp Plus DNA ladder
[Fermentas, Glen Burnie, MD]); lane 1, 1285; lane 2, YD006; lane 3,
34943. The plasmids were extracted by the standard alkaline lysis
method, digested with PstI (New England Biolabs), and electropho-
resed in a 0.7% agarose gel.
TABLE 1. Susceptibility of E. coli strains to representative -lactams
-Lactam
MIC (g/ml) for E. coli strain:
1285
(CMY-33)
YD006
(CMY-33)
34943
(CMY-44)
DH10B
(pCMY-33)a
DH10B
(pCMY-44)a
DH10B
(pCMY-2)a
DH10B
(pBCSK)
Ampicillin 256 128 256 256 256 256 3
Piperacillin 256 12 256 64 32 128 2
Piperacillin-tazobactam 128 2 96 6 16 4 1
Cefuroxime 256 96 256 128 64 256 6
Ceftazidime 256 256 256 256 256 256 0.5
Cefotaxime 256 8 32 12 8 16 0.064
Cefoxitin 256 24 256 24 32 256 6
Cefepime 96 6 32 6 3 0.25 0.032
Aztreonam 64 6 24 16 4 8 0.064
Ertapenem 1 0.064 4 0.032 0.064 0.094 0.012
a Isogenic strains of E. coli DH10B with pBCSK vector containing blaCMY-33, blaCMY-44, and blaCMY-2, respectively.
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mid-mediated AmpCs has significant implications for infec-
tion control measures.
Nucleotide sequence accession numbers. The sequences de-
termined in this study appear in the GenBank/EMBL/DDBJ
database under accession numbers EU496816 and FJ437066.
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FIG. 2. A sequence alignment of amino acid residues in the H-10 helix region of class C -lactamases. Partial amino acid sequences of CMY-33
(GenBank accession no. EU496816), CMY-43 (GenBank accession no. FJ437066), and CMY-2 (GenBank accession no. X91840) are aligned along
with AmpC -lactamases of Escherichia coli HKY28 (AB108683), Enterobacter cloacae CHE (AJ278994), and Serratia marcescens HD (AY336102).
Amino acids within the R2 loop are represented by a square box. The numbering scheme of the amino acid residues of P99 is adopted (6).
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